<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00300430</url>
  </required_header>
  <id_info>
    <org_study_id>M05-758</org_study_id>
    <nct_id>NCT00300430</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.</brief_title>
  <official_title>A Long-Term, Open-Label, Safety Extension Study of the Combination of Fenofibric Acid and Statin Therapy for Subjects With Mixed Dyslipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to test the safety and the effects of using an
      investigational drug regimen; once daily ABT-335 (Investigational drug) administered in
      combination with once daily atorvastatin calcium, rosuvastatin calcium or simvastatin in
      patients with abnormal lipid levels in the blood.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects Reporting Adverse Events During Combination Therapy, Either in the Preceding Double-Blind Studies or in This Open-Label Study</measure>
    <time_frame>Anytime after initiation of combination therapy (either in the double-blind or open-label study) to within 30 days after the last dose of combination therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median Percent Change in Triglycerides From Baseline to Week 52 of the Open-Label Study</measure>
    <time_frame>Baseline to Week 52 of the open-label study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change in High-Density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 52 of the Open-Label Study</measure>
    <time_frame>Baseline to Week 52 of the open-label study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change in Direct Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 52 of the Open-Label Study</measure>
    <time_frame>Baseline to Week 52 of the open-label study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Week 52 in This Open-Label Study</measure>
    <time_frame>Baseline to Week 52 in this open-label study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change in Very Low-Density Lipoprotein Cholesterol (VLDL-C) From Baseline to Week 52 of the Open-Label Study</measure>
    <time_frame>Baseline to Week 52 of the open-label study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change in Total Cholesterol From Baseline to Week 52 of the Open-Label Study</measure>
    <time_frame>Baseline to Week 52 of the open-label study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change in Apolipoprotein B (Apo B) From Baseline to Week 52 of the Open-Label Study</measure>
    <time_frame>Baseline to Week 52 of the open-label study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Percent Change in High-Sensitivity C-Reactive Protein (hsCRP) From Baseline to Week 52 of the Open-Label Study</measure>
    <time_frame>Baseline to Week 52 of the open-label study</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1911</enrollment>
  <condition>Dyslipidemia</condition>
  <condition>Coronary Heart Disease</condition>
  <condition>Mixed Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 mg drug and ABT-335</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>40 mg drug and ABT 335</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>40 mg drug and ABT-335</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-335 and rosuvastatin calcium</intervention_name>
    <description>ABT-335 135 mg plus rosuvastatin calcium daily, 52 weeks</description>
    <arm_group_label>A</arm_group_label>
    <other_name>ABT-335</other_name>
    <other_name>TRILIPIX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-335 and atorvastatin calcium</intervention_name>
    <description>ABT-335 135 mg plus atorvastatin calcium daily, 52 weeks</description>
    <arm_group_label>B</arm_group_label>
    <other_name>ABT-335</other_name>
    <other_name>TRILIPIX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-335 and simvastatin</intervention_name>
    <description>ABT-335 135 mg plus simvastatin daily, 52 weeks</description>
    <arm_group_label>C</arm_group_label>
    <other_name>ABT-335</other_name>
    <other_name>TRILIPIX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult male and female subjects who voluntarily sign the informed consent.

          -  Subject has successfully completed one of the three ABT-335, rosuvastatin, simvastatin
             and atorvastatin combination therapy studies.

        Exclusion Criteria:

          -  Subject is using or will use investigational medications, except as approved by
             Abbott.

          -  Subject has prematurely discontinued his/her initial therapy one of the prior ABT-335,
             rosuvastatin, simvastatin and atorvastatin calcium combination therapy studies.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Global Medical Information</name>
      <address>
        <city>North Chicago</city>
        <state>Illinois</state>
        <zip>60064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2006</study_first_submitted>
  <study_first_submitted_qc>March 7, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2006</study_first_posted>
  <results_first_submitted>March 10, 2009</results_first_submitted>
  <results_first_submitted_qc>June 3, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 23, 2009</results_first_posted>
  <last_update_submitted>June 3, 2009</last_update_submitted>
  <last_update_submitted_qc>June 3, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 23, 2009</last_update_posted>
  <responsible_party>
    <name_title>Maureen Kelly, MD</name_title>
    <organization>Abbott</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Fenofibrate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>1895 subjects were treated in this study. 306 others who did not enroll in this study but were treated with combo therapy in preceding double-blind studies are included in analyses of adverse events. Six subjects were enrolled, but never received study drug. An additional 10 subjects from a site that was closed were not included in any analysis.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ABT-335 + 20 mg Rosuvastatin</title>
          <description>ABT-335 and 20 mg rosuvastatin combination therapy</description>
        </group>
        <group group_id="P2">
          <title>ABT-335 + 40 mg Simvastatin</title>
          <description>ABT-335 and 40 mg simvastatin combination therapy</description>
        </group>
        <group group_id="P3">
          <title>ABT-335 + 40 mg Atorvastatin</title>
          <description>ABT-335 and 40 mg atorvastatin combination therapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1186">&quot;Started&quot; = received combo therapy in double-blind and/or open-label study.</participants>
                <participants group_id="P2" count="514">&quot;Started&quot; = received combo therapy in double-blind and/or open-label study.</participants>
                <participants group_id="P3" count="501">&quot;Started&quot; = received combo therapy in double-blind and/or open-label study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="819">&quot;Completed&quot; = completed both the double-blind and open-label studies.</participants>
                <participants group_id="P2" count="345">&quot;Completed&quot; = completed both the double-blind and open-label studies.</participants>
                <participants group_id="P3" count="350">&quot;Completed&quot; = completed both the double-blind and open-label studies.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="367"/>
                <participants group_id="P2" count="169"/>
                <participants group_id="P3" count="151"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ABT-335 + 20 mg Rosuvastatin</title>
          <description>ABT-335 and 20 mg rosuvastatin combination therapy</description>
        </group>
        <group group_id="B2">
          <title>ABT-335 + 40 mg Simvastatin</title>
          <description>ABT-335 and 40 mg simvastatin combination therapy</description>
        </group>
        <group group_id="B3">
          <title>ABT-335 + 40 mg Atorvastatin</title>
          <description>ABT-335 and 40 mg atorvastatin combination therapy</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1186"/>
            <count group_id="B2" value="514"/>
            <count group_id="B3" value="501"/>
            <count group_id="B4" value="2201"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="965"/>
                    <measurement group_id="B2" value="440"/>
                    <measurement group_id="B3" value="397"/>
                    <measurement group_id="B4" value="1802"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="221"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="103"/>
                    <measurement group_id="B4" value="398"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.1" spread="10.79"/>
                    <measurement group_id="B2" value="54.1" spread="10.25"/>
                    <measurement group_id="B3" value="55.5" spread="10.86"/>
                    <measurement group_id="B4" value="55.0" spread="10.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="608"/>
                    <measurement group_id="B2" value="256"/>
                    <measurement group_id="B3" value="256"/>
                    <measurement group_id="B4" value="1120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="578"/>
                    <measurement group_id="B2" value="258"/>
                    <measurement group_id="B3" value="245"/>
                    <measurement group_id="B4" value="1081"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>North America</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1186"/>
                    <measurement group_id="B2" value="514"/>
                    <measurement group_id="B3" value="501"/>
                    <measurement group_id="B4" value="2201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Median Percent Change in Triglycerides From Baseline to Week 52 of the Open-label Study</title>
        <time_frame>Baseline to Week 52 of the open-label study</time_frame>
        <population>Subjects who took at least 1 dose of ABT-335 plus a statin in the preceding double-blind studies. Baseline is the last value before the first dose of combination therapy in the preceding studies. Percent changes from baseline to Week 52 in this open-label study are summarized. No imputations were made for missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>ABT-335 + 20 mg Rosuvastatin</title>
            <description>ABT-335 and 20 mg rosuvastatin combination therapy</description>
          </group>
          <group group_id="O2">
            <title>ABT-335 + 40 mg Simvastatin</title>
            <description>ABT-335 and 40 mg simvastatin combination therapy</description>
          </group>
          <group group_id="O3">
            <title>ABT-335 + 40 mg Atorvastatin</title>
            <description>ABT-335 and 40 mg atorvastatin combination therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Median Percent Change in Triglycerides From Baseline to Week 52 of the Open-label Study</title>
          <population>Subjects who took at least 1 dose of ABT-335 plus a statin in the preceding double-blind studies. Baseline is the last value before the first dose of combination therapy in the preceding studies. Percent changes from baseline to Week 52 in this open-label study are summarized. No imputations were made for missing values.</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-53.0" spread="27.67" lower_limit="-92.7" upper_limit="87.9"/>
                    <measurement group_id="O2" value="-47.7" spread="24.62" lower_limit="-89.7" upper_limit="74.8"/>
                    <measurement group_id="O3" value="-56.2" spread="24.56" lower_limit="-92.5" upper_limit="60.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 52 of the Open-label Study</title>
        <time_frame>Baseline to Week 52 of the open-label study</time_frame>
        <population>Subjects who took at least 1 dose of ABT-335 plus a statin in the preceding double-blind studies. Baseline is the last value before the first dose of combination therapy in the preceding studies. Percent changes from baseline to Week 52 in this open-label study are summarized. No imputations were made for missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>ABT-335 + 20 mg Rosuvastatin</title>
            <description>ABT-335 and 20 mg rosuvastatin combination therapy</description>
          </group>
          <group group_id="O2">
            <title>ABT-335 + 40 mg Simvastatin</title>
            <description>ABT-335 and 40 mg simvastatin combination therapy</description>
          </group>
          <group group_id="O3">
            <title>ABT-335 + 40 mg Atorvastatin</title>
            <description>ABT-335 and 40 mg atorvastatin combination therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 52 of the Open-label Study</title>
          <population>Subjects who took at least 1 dose of ABT-335 plus a statin in the preceding double-blind studies. Baseline is the last value before the first dose of combination therapy in the preceding studies. Percent changes from baseline to Week 52 in this open-label study are summarized. No imputations were made for missing values.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.2" spread="23.22"/>
                    <measurement group_id="O2" value="25.1" spread="25.08"/>
                    <measurement group_id="O3" value="19.4" spread="20.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Change in Direct Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 52 of the Open-label Study</title>
        <time_frame>Baseline to Week 52 of the open-label study</time_frame>
        <population>Subjects who took at least 1 dose of ABT-335 plus a statin in the preceding double-blind studies. Baseline is the last value before the first dose of combination therapy in the preceding studies. Percent changes from baseline to Week 52 in this open-label study are summarized. No imputations were made for missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>ABT-335 + 20 mg Rosuvastatin</title>
            <description>ABT-335 and 20 mg rosuvastatin combination therapy</description>
          </group>
          <group group_id="O2">
            <title>ABT-335 + 40 mg Simvastatin</title>
            <description>ABT-335 and 40 mg simvastatin combination therapy</description>
          </group>
          <group group_id="O3">
            <title>ABT-335 + 40 mg Atorvastatin</title>
            <description>ABT-335 and 40 mg atorvastatin combination therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change in Direct Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 52 of the Open-label Study</title>
          <population>Subjects who took at least 1 dose of ABT-335 plus a statin in the preceding double-blind studies. Baseline is the last value before the first dose of combination therapy in the preceding studies. Percent changes from baseline to Week 52 in this open-label study are summarized. No imputations were made for missing values.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="283"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.6" spread="20.77"/>
                    <measurement group_id="O2" value="-30.2" spread="21.83"/>
                    <measurement group_id="O3" value="-38.1" spread="19.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Week 52 in This Open-label Study</title>
        <time_frame>Baseline to Week 52 in this open-label study</time_frame>
        <population>Subjects who took at least 1 dose of ABT-335 plus a statin in the preceding double-blind studies. Baseline is the last value before the first dose of combination therapy in the preceding studies. Percent changes from baseline to Week 52 in this open-label study are summarized. No imputations were made for missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>ABT-335 + 20 mg Rosuvastatin</title>
            <description>ABT-335 and 20 mg rosuvastatin combination therapy</description>
          </group>
          <group group_id="O2">
            <title>ABT-335 + 40 mg Simvastatin</title>
            <description>ABT-335 and 40 mg simvastatin combination therapy</description>
          </group>
          <group group_id="O3">
            <title>ABT-335 + 40 mg Atorvastatin</title>
            <description>ABT-335 and 40 mg atorvastatin combination therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Week 52 in This Open-label Study</title>
          <population>Subjects who took at least 1 dose of ABT-335 plus a statin in the preceding double-blind studies. Baseline is the last value before the first dose of combination therapy in the preceding studies. Percent changes from baseline to Week 52 in this open-label study are summarized. No imputations were made for missing values.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-48.8" spread="15.80"/>
                    <measurement group_id="O2" value="-36.6" spread="16.90"/>
                    <measurement group_id="O3" value="-44.3" spread="15.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Change in Very Low-density Lipoprotein Cholesterol (VLDL-C) From Baseline to Week 52 of the Open-label Study</title>
        <time_frame>Baseline to Week 52 of the open-label study</time_frame>
        <population>Subjects who took at least 1 dose of ABT-335 plus a statin in the preceding double-blind studies. Baseline is the last value before the first dose of combination therapy in the preceding studies. Percent changes from baseline to Week 52 in this open-label study are summarized. No imputations were made for missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>ABT-335 + 20 mg Rosuvastatin</title>
            <description>ABT-335 and 20 mg rosuvastatin combination therapy</description>
          </group>
          <group group_id="O2">
            <title>ABT-335 + 40 mg Simvastatin</title>
            <description>ABT-335 and 40 mg simvastatin combination therapy</description>
          </group>
          <group group_id="O3">
            <title>ABT-335 + 40 mg Atorvastatin</title>
            <description>ABT-335 and 40 mg atorvastatin combination therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change in Very Low-density Lipoprotein Cholesterol (VLDL-C) From Baseline to Week 52 of the Open-label Study</title>
          <population>Subjects who took at least 1 dose of ABT-335 plus a statin in the preceding double-blind studies. Baseline is the last value before the first dose of combination therapy in the preceding studies. Percent changes from baseline to Week 52 in this open-label study are summarized. No imputations were made for missing values.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="272"/>
                <count group_id="O2" value="117"/>
                <count group_id="O3" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-56.9" spread="27.85"/>
                    <measurement group_id="O2" value="-37.7" spread="63.12"/>
                    <measurement group_id="O3" value="-52.2" spread="36.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Change in Total Cholesterol From Baseline to Week 52 of the Open-label Study</title>
        <time_frame>Baseline to Week 52 of the open-label study</time_frame>
        <population>Subjects who took at least 1 dose of ABT-335 plus a statin in the preceding double-blind studies. Baseline is the last value before the first dose of combination therapy in the preceding studies. Percent changes from baseline to Week 52 in this open-label study are summarized. No imputations were made for missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>ABT-335 + 20 mg Rosuvastatin</title>
            <description>ABT-335 and 20 mg rosuvastatin combination therapy</description>
          </group>
          <group group_id="O2">
            <title>ABT-335 + 40 mg Simvastatin</title>
            <description>ABT-335 and 40 mg simvastatin combination therapy</description>
          </group>
          <group group_id="O3">
            <title>ABT-335 + 40 mg Atorvastatin</title>
            <description>ABT-335 and 40 mg atorvastatin combination therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change in Total Cholesterol From Baseline to Week 52 of the Open-label Study</title>
          <population>Subjects who took at least 1 dose of ABT-335 plus a statin in the preceding double-blind studies. Baseline is the last value before the first dose of combination therapy in the preceding studies. Percent changes from baseline to Week 52 in this open-label study are summarized. No imputations were made for missing values.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.9" spread="13.14"/>
                    <measurement group_id="O2" value="-27.5" spread="14.60"/>
                    <measurement group_id="O3" value="-35.0" spread="13.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Change in Apolipoprotein B (Apo B) From Baseline to Week 52 of the Open-label Study</title>
        <time_frame>Baseline to Week 52 of the open-label study</time_frame>
        <population>Subjects who took at least 1 dose of ABT-335 plus a statin in the preceding double-blind studies. Baseline is the last value before the first dose of combination therapy in the preceding studies. Percent changes from baseline to Week 52 in this open-label study are summarized. No imputations were made for missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>ABT-335 + 20 mg Rosuvastatin</title>
            <description>ABT-335 and 20 mg rosuvastatin combination therapy</description>
          </group>
          <group group_id="O2">
            <title>ABT-335 + 40 mg Simvastatin</title>
            <description>ABT-335 and 40 mg simvastatin combination therapy</description>
          </group>
          <group group_id="O3">
            <title>ABT-335 + 40 mg Atorvastatin</title>
            <description>ABT-335 and 40 mg atorvastatin combination therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change in Apolipoprotein B (Apo B) From Baseline to Week 52 of the Open-label Study</title>
          <population>Subjects who took at least 1 dose of ABT-335 plus a statin in the preceding double-blind studies. Baseline is the last value before the first dose of combination therapy in the preceding studies. Percent changes from baseline to Week 52 in this open-label study are summarized. No imputations were made for missing values.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="277"/>
                <count group_id="O2" value="115"/>
                <count group_id="O3" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-44.8" spread="15.40"/>
                    <measurement group_id="O2" value="-35.5" spread="14.85"/>
                    <measurement group_id="O3" value="-42.9" spread="14.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects Reporting Adverse Events During Combination Therapy, Either in the Preceding Double-blind Studies or in This Open-label Study</title>
        <time_frame>Anytime after initiation of combination therapy (either in the double-blind or open-label study) to within 30 days after the last dose of combination therapy</time_frame>
        <population>Subjects who took at least 1 dose of ABT-335 plus a statin in the preceding double-blind studies or in this open-label study. All adverse events in the preceding studies or in this study occurring with exposure to combination therapy are summarized.</population>
        <group_list>
          <group group_id="O1">
            <title>ABT-335 + 20 mg Rosuvastatin</title>
            <description>ABT-335 and 20 mg rosuvastatin combination therapy</description>
          </group>
          <group group_id="O2">
            <title>ABT-335 + 40 mg Simvastatin</title>
            <description>ABT-335 and 40 mg simvastatin combination therapy</description>
          </group>
          <group group_id="O3">
            <title>ABT-335 + 40 mg Atorvastatin</title>
            <description>ABT-335 and 40 mg atorvastatin combination therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Reporting Adverse Events During Combination Therapy, Either in the Preceding Double-blind Studies or in This Open-label Study</title>
          <population>Subjects who took at least 1 dose of ABT-335 plus a statin in the preceding double-blind studies or in this open-label study. All adverse events in the preceding studies or in this study occurring with exposure to combination therapy are summarized.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1186"/>
                <count group_id="O2" value="514"/>
                <count group_id="O3" value="501"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="86"/>
                    <measurement group_id="O3" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Percent Change in High-sensitivity C-reactive Protein (hsCRP) From Baseline to Week 52 of the Open-label Study</title>
        <time_frame>Baseline to Week 52 of the open-label study</time_frame>
        <population>Subjects who took at least 1 dose of ABT-335 plus a statin in the preceding double-blind studies. Baseline is the last value before the first dose of combination therapy in the preceding studies. Percent changes from baseline to Week 52 in this open-label study are summarized. No imputations were made for missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>ABT-335 + 20 mg Rosuvastatin</title>
            <description>ABT-335 and 20 mg rosuvastatin combination therapy</description>
          </group>
          <group group_id="O2">
            <title>ABT-335 + 40 mg Simvastatin</title>
            <description>ABT-335 and 40 mg simvastatin combination therapy</description>
          </group>
          <group group_id="O3">
            <title>ABT-335 + 40 mg Atorvastatin</title>
            <description>ABT-335 and 40 mg atorvastatin combination therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Median Percent Change in High-sensitivity C-reactive Protein (hsCRP) From Baseline to Week 52 of the Open-label Study</title>
          <population>Subjects who took at least 1 dose of ABT-335 plus a statin in the preceding double-blind studies. Baseline is the last value before the first dose of combination therapy in the preceding studies. Percent changes from baseline to Week 52 in this open-label study are summarized. No imputations were made for missing values.</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="279"/>
                <count group_id="O2" value="117"/>
                <count group_id="O3" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.87" spread="265.37" lower_limit="-94.5" upper_limit="1166.0"/>
                    <measurement group_id="O2" value="-27.72" spread="93.62" lower_limit="-99.8" upper_limit="2558.5"/>
                    <measurement group_id="O3" value="-39.13" spread="70.99" lower_limit="-95.4" upper_limit="384.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>ABT-335 + 20 mg Rosuvastatin</title>
          <description>ABT-335 and 20 mg rosuvastatin combination therapy</description>
        </group>
        <group group_id="E2">
          <title>ABT-335 + 40 mg Simvastatin</title>
          <description>ABT-335 and 40 mg simvastatin combination therapy</description>
        </group>
        <group group_id="E3">
          <title>ABT-335 + 40 mg Atorvastatin</title>
          <description>ABT-335 and 40 mg atorvastatin combination therapy</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 9.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="85"/>
                <counts group_id="E2" subjects_affected="40"/>
                <counts group_id="E3" subjects_affected="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Myocardial ischemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Arnold-Chiari malformation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperparathyroidism primary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Vitreous detachment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Enterocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Latex allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal wall infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Bacteremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Hepatitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Device failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Post procedural hematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Post procedural sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Postoperative fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Ultrasound kidney abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Carcinoid tumor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Glioblastoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Lip and/or oral cavity cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Ovarian adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Pituitary tumor benign</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Brain stem infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Normal pressure hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Transient ischemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Trigeminal neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Unresponsive to stimuli</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Glomerulonephritis proliferative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Menstruation irregular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Rectocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Uterine pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Femoral arterial stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5.0</frequency_threshold>
        <default_vocab>MedDRA 9.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="646"/>
                <counts group_id="E2" subjects_affected="308"/>
                <counts group_id="E3" subjects_affected="283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="116" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="58" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="145" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="57" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="118" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="160" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="74" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="1186"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Not to publish or present the results before the publication of the multi-center investigator paper, but in no event shall be so restricted after the expiration of twelve (12) months from completion of the studies at all sites. Any presentation or publication to be submitted to Sponsor (in draft of the same) for Sponsor review and comment.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This was an open-label study designed to assess the longer-term safety of the combination therapies. Evaluation of efficacy outcomes was a secondary objective.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Medical Information Specialist</name_or_title>
      <organization>Abbott</organization>
      <phone>800-633-9110</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

